Investing.com -- Roivant Sciences Ltd (NASDAQ:ROIV) announced Tuesday that the Food and Drug Administration has accepted and granted priority review to the New Drug Application for brepocitinib in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results